Institute of Psychiatric and Psychosomatic Psychotherapy, Central Institute of Mental Health Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
McLean Hospital, Harvard Medical School, Boston, Massachusetts.
JAMA Psychiatry. 2020 Dec 1;77(12):1235-1245. doi: 10.1001/jamapsychiatry.2020.2148.
Childhood abuse significantly increases the risk of developing posttraumatic stress disorder (PTSD), often accompanied by symptoms of borderline personality disorder (BPD) and other co-occurring mental disorders. Despite the high prevalence, systematic evaluations of evidence-based treatments for PTSD after childhood abuse are sparse.
To compare the efficacy of dialectical behavior therapy for PTSD (DBT-PTSD), a new, specifically designed, phase-based treatment program, against that of cognitive processing therapy (CPT), one of the best empirically supported treatments for PTSD.
DESIGN, SETTING, AND PARTICIPANTS: From January 2014 to October 2016, women who sought treatment were included in a multicenter randomized clinical trial with blinded outcome assessments at 3 German university outpatient clinics. The participants were prospectively observed for 15 months. Women with childhood abuse-associated PTSD who additionally met 3 or more DSM-5 criteria for BPD, including affective instability, were included. Data analysis took place from October 2018 to December 2019.
Participants received equal dosages and frequencies of DBT-PTSD or CPT, up to 45 individual sessions within 1 year and 3 additional sessions during the following 3 months.
The predefined primary outcome was the course of the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score from randomization to month 15. Intent-to-treat analyses based on dimensional CAPS-5 scores were complemented by categorical outcome measures assessing symptomatic remission, reliable improvement, and reliable recovery.
Of 955 consecutive individuals assessed for eligibility, 193 were randomized (DBT-PTSD, 98; CPT, 95; mean [SD] age, 36.3 [11.1] years) and included in the intent-to-treat analyses. Analysis revealed significantly improved CAPS-5 scores in both groups (effect sizes: DBT-PTSD: d, 1.35; CPT: d, 0.98) and a small but statistically significant superiority of DBT-PTSD (group difference: 4.82 [95% CI, 0.67-8.96]; P = .02; d, 0.33). Compared with the CPT group, participants in the DBT-PTSD group were less likely to drop out early (37 [39.0%] vs 25 [25.5%]; P = .046) and had higher rates of symptomatic remission (35 [40.7%] vs 52 [58.4%]; P = .02), reliable improvement (53 [55.8%] vs 73 [74.5%]; P = .006), and reliable recovery (34 [38.6%] vs 52 [57.1%]; P = .01).
These findings support the efficacy of DBT-PTSD and CPT in the treatment of women with childhood abuse-associated complex PTSD. Results pertaining to the primary outcomes favored DBT-PTSD. The study shows that even severe childhood abuse-associated PTSD with emotion dysregulation can be treated efficaciously.
German Clinical Trials Register: DRKS00005578.
儿童期虐待显著增加创伤后应激障碍 (PTSD) 的发病风险,常伴有边缘型人格障碍 (BPD) 和其他共病精神障碍的症状。尽管患病率很高,但针对儿童期虐待后 PTSD 的循证治疗进行系统评估的研究却很少。
比较专门设计的基于阶段的新治疗方案辩证行为治疗创伤后应激障碍 (DBT-PTSD) 与认知加工治疗 (CPT) 的疗效,CPT 是 PTSD 的最佳循证治疗之一。
设计、设置和参与者:从 2014 年 1 月至 2016 年 10 月,在德国 3 家大学门诊诊所,对寻求治疗的女性进行了一项多中心随机临床试验,采用盲法对结局进行评估。对参与者进行了 15 个月的前瞻性观察。纳入患有与儿童期虐待相关的 PTSD 且符合 DSM-5 中 3 项或更多 BPD 标准的女性,包括情感不稳定,纳入研究。数据分析于 2018 年 10 月至 2019 年 12 月进行。
参与者接受等量和频率的 DBT-PTSD 或 CPT 治疗,在 1 年内最多接受 45 次个体治疗,随后的 3 个月内再接受 3 次额外治疗。
预先设定的主要结局是从随机分组到第 15 个月的临床医生管理的 PTSD 量表 DSM-5 评分(CAPS-5)的变化。基于维度性 CAPS-5 评分的意向治疗分析,辅以评估症状缓解、可靠改善和可靠恢复的分类结局指标。
在评估的 955 名连续合格个体中,有 193 名被随机分配(DBT-PTSD,98 名;CPT,95 名;平均[标准差]年龄,36.3[11.1]岁)并纳入意向治疗分析。结果显示,两组的 CAPS-5 评分均显著改善(效应量:DBT-PTSD:d,1.35;CPT:d,0.98),DBT-PTSD 具有较小但统计学上显著的优势(组间差异:4.82[95%CI,0.67-8.96];P=0.02;d,0.33)。与 CPT 组相比,DBT-PTSD 组的早期退出率较低(37[39.0%] vs 25[25.5%];P=0.046),症状缓解率较高(35[40.7%] vs 52[58.4%];P=0.02),可靠改善率较高(53[55.8%] vs 73[74.5%];P=0.006),可靠恢复率较高(34[38.6%] vs 52[57.1%];P=0.01)。
这些发现支持 DBT-PTSD 和 CPT 在治疗与儿童期虐待相关的复杂 PTSD 女性中的疗效。主要结局相关的结果有利于 DBT-PTSD。研究表明,即使是伴有情绪失调的严重与儿童期虐待相关的 PTSD 也可以有效治疗。
德国临床试验注册处:DRKS00005578。